Founded in 2009, Celgene Global Health (CGH) focuses on delivering our promise to put patients first through the pursuit of innovative solutions to healthcare challenges in the developing world. This work is based on our belief that innovative therapies and healthcare partnerships are essential components to long term progress and prosperity around the globe.
Celgene has more than 400,000 compounds in our library across multiple platforms which have potential applications to treat neglected diseases of the developing world (DDW). These diseases affect the most impoverished around the world. CGH is collaborating with Product Development Partnerships (PDPs), global academic institutions, non-government organizations (NGOs), public/private funding organizations, contract research organizations, contract research organizations (CROs), and other pharmaceutical organizations to evaluate our proprietary compounds for activity in neglected diseases. There are a number of CGH programs that are in various stages of development. These programs range from screening to lead optimization to clinical trials including animal testing provide an opportunity for CGH to explore and develop its library of proprietary assets.
CGH is also committed to providing support to enhance the infrastructure and capability of health systems and local medical experts in the developing world to expand access to safe and effective medicines. This work in improving access to medicines is based on a belief that the most successful approaches will come from public-private partnerships, collaboration with local experts and sharing best practices.